The market potential for the future utilization of surgical sealants, glues, wound closure and anti-adhesion products is closely tied to the growth in the number of procedures performed, as well as the gradual adoption of these products for multiple uses (sealing, hemostasis and even anti-adhesion). Use of these technologies will eventually become routine in surgical and other clinical practices. Demographic forces are driving potential caseloads and therefore are also a factor in market potential. Changing regulatory demands will continue to influence the markets for these products, although this influence may as equally drive as limit demand.
Clinical demand (i.e., growth in indicated caseload) for these advanced products is not changing substantially with annual growth rates in wound types typically under 4%, with the exception of chronic wounds, which are growing globally at better than 7% (chronic wounds do not represent a significant indication for sealants, glues, hemostats and similar products).
In the aggregate, product adoption trends and the demographic forces, combined with new product introductions, are expected to accelerate market growth, based not on new indication but on penetration of caseload otherwise served by the traditional wound closure products like sutures, staples, clips and even tapes (see graph at right). There continues to be a significant and increasing potential for advanced products penetrating traditional products, with the total caseload targeted by new and established products likely to exceed 100 million procedures globally. Growth in use of surgical sealants, glues, wound closure and anti- adhesion products is predicted to exceed double-digit annual rates for new products, and for established products in geographic markets that have yet to be fully developed, with annual growth in advanced products nearing or exceeding 10% while annual sales growth in sutures, staples, clips and tapes is considerably below this.
There are also multiple new technologies, delivery systems and products in development, some of which may come onto the market during the forecast period or shortly thereafter. In parallel with the invention of new products, in several instances new delivery systems have had to be developed. For example, new delivery systems have evolved to spray liquid hemostat solutions such as thrombin onto surgical sites to improve speed of hemostasis. Fibrin sealant is supplied as two powders that need to be solubilized and then mixed immediately prior to application to the surgical site. This has led to the development of a number of sophisticated medical delivery devices and even solubilized product formulations or single component systems that enable immediate use in the surgical theater.
Source: "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2017", Report #S190, MedMarket Diligence, LLC.